De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Incyte Beheer
Beheer criteriumcontroles 4/4
De CEO Incyte's is Herve Hoppenot, benoemd in Jan2014, heeft een ambtstermijn van 10.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 16.66M, bestaande uit 7.8% salaris en 92.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.2% van de aandelen van het bedrijf, ter waarde $ 25.25M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.8 jaar en 7.8 jaar.
Belangrijke informatie
Herve Hoppenot
Algemeen directeur
US$16.7m
Totale compensatie
Percentage CEO-salaris | 7.8% |
Dienstverband CEO | 10.8yrs |
Eigendom CEO | 0.2% |
Management gemiddelde ambtstermijn | 8.8yrs |
Gemiddelde ambtstermijn bestuur | 7.8yrs |
Recente managementupdates
Recent updates
Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data
Aug 19Incyte: The Worst Has Been Avoided
Jun 16It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year
Jun 06We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings
May 07Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)
May 03Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)
Apr 26Incyte: A Potential GARP Superstar
Feb 27Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today
Feb 02Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today
Oct 31Knight's affiliate files for Brazilian approval of cancer drug tafasitamab
Oct 07Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable Chart
Sep 29Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia
Sep 15Incyte wins approval of Pemazyre for rare blood cancer
Aug 26Incyte Q2 results beat on top and bottom lines as net income soars 27%; shares down 6%
Aug 02With EPS Growth And More, Incyte (NASDAQ:INCY) Makes An Interesting Case
Jul 27Incyte Corp. Should Move Higher (Technical Analysis)
Jul 18Incyte: Growth Drivers Are Coming
Jun 17Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Jun 30 2024 | n/a | n/a | US$97m |
Mar 31 2024 | n/a | n/a | US$745m |
Dec 31 2023 | US$17m | US$1m | US$598m |
Sep 30 2023 | n/a | n/a | US$425m |
Jun 30 2023 | n/a | n/a | US$366m |
Mar 31 2023 | n/a | n/a | US$324m |
Dec 31 2022 | US$17m | US$1m | US$341m |
Sep 30 2022 | n/a | n/a | US$876m |
Jun 30 2022 | n/a | n/a | US$945m |
Mar 31 2022 | n/a | n/a | US$933m |
Dec 31 2021 | US$14m | US$1m | US$949m |
Sep 30 2021 | n/a | n/a | US$535m |
Jun 30 2021 | n/a | n/a | US$338m |
Mar 31 2021 | n/a | n/a | US$478m |
Dec 31 2020 | US$16m | US$1m | -US$296m |
Sep 30 2020 | n/a | n/a | -US$335m |
Jun 30 2020 | n/a | n/a | -US$191m |
Mar 31 2020 | n/a | n/a | -US$376m |
Dec 31 2019 | US$15m | US$1m | US$447m |
Sep 30 2019 | n/a | n/a | US$405m |
Jun 30 2019 | n/a | n/a | US$306m |
Mar 31 2019 | n/a | n/a | US$253m |
Dec 31 2018 | US$9m | US$996k | US$109m |
Sep 30 2018 | n/a | n/a | -US$109m |
Jun 30 2018 | n/a | n/a | -US$102m |
Mar 31 2018 | n/a | n/a | -US$167m |
Dec 31 2017 | US$16m | US$967k | -US$313m |
Compensatie versus markt: De totale vergoeding ($USD 16.66M ) Herve } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 13.04M ).
Compensatie versus inkomsten: De vergoeding van Herve is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Herve Hoppenot (64 yo)
10.8yrs
Tenure
US$16,659,526
Compensatie
Mr. Herve Hoppenot has been the Chairman of the Board at Incyte Corporation since May 2015 and as its Chief Executive Officer and was President since January 13, 2014 until June 05, 2023. Mr. Hoppenot serv...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO & Chairman | 10.8yrs | US$16.66m | 0.20% $ 26.0m | |
President and Head of Research & Development | 1.4yrs | US$16.57m | 0.00087% $ 114.0k | |
Executive VP & CFO | 5.7yrs | US$5.08m | 0.019% $ 2.5m | |
Executive VP & GM of North America | 9.3yrs | US$4.09m | 0.0062% $ 812.7k | |
Executive VP & Chief Medical Officer | 9.6yrs | US$5.63m | 0.0013% $ 174.3k | |
VP of Finance | 2.6yrs | geen gegevens | 0.0047% $ 614.8k | |
Executive VP & Head of Global Technical Operations | 8.8yrs | geen gegevens | 0.019% $ 2.5m | |
Head of Investor Relations | no data | geen gegevens | geen gegevens | |
Executive VP | less than a year | geen gegevens | geen gegevens | |
Vice President of Investor Relations & Corporate Communications | no data | geen gegevens | geen gegevens | |
Executive Vice President of Human Resources | 22.2yrs | US$1.31m | 0.030% $ 3.9m | |
Executive VP of Global Medical Affairs | no data | US$3.30m | 0.0044% $ 578.1k |
8.8yrs
Gemiddelde duur
60yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van INCY is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.8 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO & Chairman | 10.8yrs | US$16.66m | 0.20% $ 26.0m | |
Independent Director | 9.8yrs | US$478.76k | 0.0080% $ 1.1m | |
Independent Lead Director | 22.9yrs | US$512.76k | 0.14% $ 19.0m | |
Independent Director | 3.1yrs | US$454.76k | 0.0031% $ 402.4k | |
Independent Director | 7.8yrs | US$466.26k | 0.0073% $ 951.7k | |
Independent Director | 4.8yrs | US$482.26k | 0.0070% $ 920.2k | |
Independent Director | 4.6yrs | US$454.76k | 0.0042% $ 544.0k | |
Independent Director | 9.8yrs | US$479.76k | 0.0084% $ 1.1m | |
Independent Director | 2yrs | US$444.76k | 0.0015% $ 196.6k |
7.8yrs
Gemiddelde duur
64yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van INCY wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.8 jaar).